

Received: 2022.09.15 Accepted: 2022.09.15 Available online: 2022.09.15 Published: 2022.09.16

e-ISSN 1643-3750 © Med Sci Monit. 2022: 28: e938399 DOI: 10.12659/MSM.938399

Errate: Remimazolam Tosilate Sedation with Adjuvant Sufentanil in Chinese Patients with Liver Cirrhosis Undergoing Gastroscopy: A Randomized Controlled Study

- 1 YingHao Cao
- 1 Ping Chi
- 2 Chen Zhou
- 1 WenFei Lv
- 1 ZheFen Ouan
- Fu Shan Xue
- **Corresponding Author:**

Fu Shan Xue, e-mail: xuefushan@aliyun.com

1 Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, PR China

2 Department of Zoology and Physiology, University of Wyoming, Laramie, WY, USA

The results in Table 3 (highlighted) have been corrected to be consistent with the results reported in the text.

Table 3. Primary and secondary outcomes.

		Remimazolam	Propofol	P
Subjects, n		74	74	-
Primary outcome				
Endoscopist satisfaction	Satisfied	67 (90.5%)	57 (77.0%)	0.026
	Fair	6 (8.1%)	13 (17.6%)	0.085
	Unsatisfied	1 (1.4%)	4 (5.4%)	0.367
Secondary outcomes				
Respiratory depression		2 (2.7%)	13 (17.6%)	0.007
Apnea		Nil	3 (4.1%)	0.245
Body movement		6 (8.1%)	17 (23.0%)	0.043
Bradycardia		Nil	4 (5.4%)	0.1021
Hypotension		3 (4.1%)	11 (14.9%)	0.031
Nausea or vomiting		2 (2.7%)	1 (1.4%)	1.000
Somnolence		Nil	3 (4.1%)	0.245
Dizziness		1 (1.4%)	3 (4.1%)	0.621
Fever		Nil	Nil	1.000
Patient satisfaction	Satisfied	74 (100.0%)	72 (97.3%)	0.908
	Fair	Nil	2 (2.7%)	0.497
	Unsatisfied	Nil	Nil	1.000

Reference:

YingHao Cao, Ping Chi, Chen Zhou, WenFei Ly, ZheFen Quan, Fu Shan Xue: Remimazolam Tosilate Sedation with Adjuvant Sufentanil in Chinese Patients with Liver Cirrhosis Undergoing Gastroscopy: A Randomized Controlled Study. Med Sci Monit, 2022; 28: e936580. DOI: 10.12659/MSM.936580



Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/938399